A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells

Cancer Immunology, Immunotherapy

Volumn 58, Issue 7, 2009, Pages 1023-1032

  Kong, Ling Yuan ^a   Wei, Jun ^a   Sharma, Amit K ^a   Barr, Jason ^a   Abou Ghazal, Mohamed K ^a   Fokt, Izabela ^a   Weinberg, Jeffrey ^a   Rao, Ganesh ^a   Grimm, Elizabeth ^a   Priebe, Waldemar ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Central nervous system; Cytotoxic T cells; Melanoma; Regulatory T cells; STAT3; STAT3 inhibitors

Indexed keywords

PROTEIN INHIBITOR; PROTEIN KINASE ZAP 70; STAT3 PROTEIN; UNCLASSIFIED DRUG; WP 1066;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOCYTE ACTIVATION; MELANOMA; MELANOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MELANOMA; PHOSPHORYLATION; PYRIDINES; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TYRPHOSTINS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 67349277417     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0618-y     Document Type: Article

References (38)

1. M Ahmad RC Rees SA Ali 2004 Escape from immunotherapy: possible mechanisms that influence tumor regression/progression Cancer Immunol Immunother 53 844 854 (Pubitemid 39312652)
2. MB Atkins L Kunkel M Sznol SA Rosenberg 2000 High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update Cancer J Sci Am 6 Suppl 1 S11 S14 (Pubitemid 30117631)
3. MB Atkins MT Lotze JP Dutcher RI Fisher G Weiss K Margolin J Abrams M Sznol D Parkinson M Hawkins C Paradise L Kunkel SA Rosenberg 1999 High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 2105 2116 (Pubitemid 29318842)
4. S Chattopadhyay NG Chakraborty B Mukherji 2005 Regulatory T cells and tumor immunity Cancer Immunol Immunother 54 1153 1161 (Pubitemid 41416947)
5. JE Darnell Jr 2002 Transcription factors as targets for cancer therapy Nat Rev Cancer 2 740 749 (Pubitemid 37328909)
6. PE Fecci DA Mitchell JF Whitesides W Xie AH Friedman GE Archer JE Herndon 2nd DD Bigner G Dranoff JH Sampson 2006 Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma Cancer Res 66 3294 3302
7. PE Fecci H Ochiai DA Mitchell PM Grossi AE Sweeney GE Archer T Cummings JP Allison DD Bigner JH Sampson 2007 Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function Clin Cancer Res 13 2158 2167 (Pubitemid 46649886)
8. PE Fecci AE Sweeney PM Grossi SK Nair CA Learn DA Mitchell X Cui TJ Cummings DD Bigner E Gilboa JH Sampson 2006 Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells Clin Cancer Res 12 4294 4305
9. K Gijbels J Van Damme P Proost W Put H Carton A Billiau 1990 Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis Eur J Immunol 20 233 235 (Pubitemid 20087053)
10. AB Heimberger LE Crotty GE Archer KR Hess CJ Wikstrand AH Friedman HS Friedman DD Bigner JH Sampson 2003 Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors Clin Cancer Res 9 4247 4254 (Pubitemid 37204046)
11. Heimberger AB, Priebe W, Fokt I, Szymanski S, Hussain SF, Kong L-Y (2007) Small molecule inhibitors for immune modulation. US 0/908, 559
12. PC Heinrich I Behrmann S Haan HM Hermanns G Muller-Newen F Schaper 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation Biochem J 374 1 20 (Pubitemid 37046923)
13. SF Hussain L-Y Kong J Jordan C Conrad T Madden I Fokt W Priebe AB Heimberger 2007 A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients Cancer Res 67 9630 9636 (Pubitemid 47621208)
14. I Kinjyo H Inoue S Hamano S Fukuyama T Yoshimura K Koga H Takaki K Himeno G Takaesu T Kobayashi A Yoshimura 2006 Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1 J Exp Med 203 1021 1031
15. LY Kong MK Abou-Ghazal J Wei A Chakraborty W Sun W Qiao GN Fuller I Fokt EA Grimm RJ Schmittling GE Archer Jr JH Sampson W Priebe AB Heimberger 2008 A novel inhibitor of STAT3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells Clin Cancer Res 14 5759 5768
16. M Kortylewski R Jove H Yu 2005 Targeting STAT3 affects melanoma on multiple fronts Cancer Metastasis Rev 24 315 327 (Pubitemid 40922802)
17. M Kortylewski M Kujawski T Wang S Wei S Zhang S Pilon-Thomas G Niu H Kay J Mule WG Kerr R Jove D Pardoll H Yu 2005 Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity Nat Med 11 1314 1321 (Pubitemid 41752912)
18. M Kurdi GW Booz 2007 Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling J Cardiovasc Pharmacol 50 126 141 (Pubitemid 47267738)
19. LT Lau AC Yu 2001 Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury J Neurotrauma 18 351 359 (Pubitemid 32230637)
20. B Li CM Chang M Yuan WG [tmp] McKenna HK Shu 2003 Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas Cancer Res 63 7443 7450 (Pubitemid 37413487)
21. Madden T, Kazerooni R, Myer J, Culotta K, Donato N, Johansen M, Kondo Y, Mack D, Priebe W (2006) The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway. In: Proceedings of the 97th American Association for Cancer Research Annual Meeting. Washington, DC
22. G Niu T Bowman M Huang S Shivers D Reintgen A Daud A Chang A Kraker R Jove H Yu 2002 Roles of activated Src and Stat3 signaling in melanoma tumor cell growth Oncogene 21 7001 7010 (Pubitemid 35252974)
23. GC Prendergast 2008 Immune escape as a fundamental trait of cancer: focus on IDO Oncogene 27 3889 3900
24. Priebe W, Donato N, Talpaz M, Fokt I, Szymanski S (2004) Novel compounds for treatment of cell proliferative diseases. 832 WO/104013214
25. Priebe W, Fokt I, Szymanski S, Madden T, Bao JI, Lesyng B, Conrad C, Kupferman M, Abbruzzese J, Myer J (2006) Design, synthesis and structure-activity relationships of novel Jak2/STAT3 signaling inhibitors. In: Proceedings of the 97th American Association for Cancer Research Annual Meeting. Washington, DC
26. P Rietschel PB Chapman 2006 Immunotherapy of melanoma Hematol Oncol Clin North Am 20 751 766 (Pubitemid 43817434)
27. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 915 (Pubitemid 39273730)
28. SA Rosenberg JC Yang SL Topalian DJ Schwartzentruber JS Weber DR Parkinson CA Seipp JH Einhorn DE White 1994 Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 907 913 (Pubitemid 24083215)
29. JA Ross ZS Nagy H Cheng SM Stepkowski RA Kirken 2007 Regulation of T cell homeostasis by JAKs and STATs Arch Immunol Ther Exp (Warsz) 55 231 245 (Pubitemid 47262712)
30. AM Sonabend CE Rolle MS Lesniak 2008 The role of regulatory T cells in malignant glioma Anticancer Res 28 1143 1150
31. H Sumimoto F Imabayashi T Iwata Y Kawakami 2006 The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J Exp Med 203 1651 1656 (Pubitemid 44036269)
32. E Tarkowski L Rosengren C Blomstrand C Wikkelso C Jensen S Ekholm A Tarkowski 1995 Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke Stroke 26 1393 1398
33. T Wang G Niu M Kortylewski L Burdelya K Shain S Zhang R Bhattacharya D Gabrilovich R Heller D Coppola W Dalton R Jove D Pardoll H Yu 2004 Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells Nat Med 10 48 54 (Pubitemid 38524698)
34. TX Xie FJ Huang KD Aldape SH Kang M Liu JE Gershenwald K Xie R Sawaya S Huang 2006 Activation of stat3 in human melanoma promotes brain metastasis Cancer Res 66 3188 3196
35. TX Xie D Wei M Liu AC Gao F Ali-Osman R Sawaya S Huang 2004 Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis Oncogene 23 3550 3560 (Pubitemid 38658421)
36. H Yu M Kortylewski D Pardoll 2007 Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment Nat Rev Immunol 7 41 51 (Pubitemid 46020826)
37. L Zhuang C Lee RA Scolyer SW [tmp] McCarthy X Zhang JF Thompson P Hersey 2007 Mcl-1, Bcl-XL and STAT3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma Mod Pathol 20 416 426 (Pubitemid 46482365)
38. E Zorn EA Nelson M Mohseni F Porcheray H Kim D Litsa R Bellucci E Raderschall C Canning RJ Soiffer DA Frank J Ritz 2006 IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo Blood 108 1571 1579 (Pubitemid 44316124)